CN106420839A - Clostridium butyricum-inulin composition as well as preparation method and application thereof - Google Patents
Clostridium butyricum-inulin composition as well as preparation method and application thereof Download PDFInfo
- Publication number
- CN106420839A CN106420839A CN201610937943.6A CN201610937943A CN106420839A CN 106420839 A CN106420839 A CN 106420839A CN 201610937943 A CN201610937943 A CN 201610937943A CN 106420839 A CN106420839 A CN 106420839A
- Authority
- CN
- China
- Prior art keywords
- butyric acid
- inulin
- acid bacteria
- composition
- intestinal
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/733—Fructosans, e.g. inulin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Molecular Biology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
The invention discloses a clostridium butyricum-inulin composition as well as a preparation method and application thereof. The composition comprises inulin and clostridium butyricum in a mass ratio of (3-8) to 1. The composition has an optimal proportion and can give full play to the synergistic effects of inulin and clostridium butyricum. The composition can be used for regulating the intestinal floras of animals to achieve the purpose that clostridium butyricum decomposes inulin to generate plenty of physiological active substances, namely butyric acids, to activate peroxysome systems, thus preventing or treating obesity, diabetes mellitus, hypertension, hyperlipidemia or tumors. The composition and the preparation method have the beneficial effects that all the raw materials are purely natural, safe and reliable, do not have any toxic or side effect and do not contain any chemical preparation; the composition is scientific and reasonable in compatibility and has definite curative effects and synergistic effects; the preparation process is simple and is easy to operate; and intestinal physiological effects can be better achieved, and good intestinal micro-ecology can be established.
Description
Technical field
The present invention relates to edible composition and its preparation and use, are exactly specifically a kind of butyric acid bacteria-inulin combination
Thing and its production and use.
Background technology
About 10 are perched in human gastrointestinal tract14The normal flora of magnitude, is 10 times of human body cell sum.The micro- life of intestinal
Thing contains miscellaneous enzyme system, can participate in host's energy, material and hereditary information transhipment etc. a series of physiological process.?
Have many studies demonstrate that, enteric microorganism can form biological barrier in intestinal, by occupation time process, nutrient competition and its be divided
The undue growth of the rejection condition pathogenic bacterium such as the various metabolites that secretes and bacteriocin and the invasion of external pathogenic bacterium.Increasingly
Many evidences show, the intestinal microbial population of structural imbalance has in obesity, diabetes, the generation of hyperlipidemia chronic diseases, development
Highly important effect.By taking hyperlipidemia as an example, hyperlipidemia sickness rate increases year by year, and China there are about 100,000,000 people with hyperlipidemia, should
The harm of disease be concealment, gradually, progressive and general, especially harm renovascular to heart and brain is great, is often cardiovascular and cerebrovascular vessel
The basis of disease incidence, such as atherosclerosiss, coronary heart disease, therefore, hyperlipemia also by person be
The source of disease ".While also can the concurrent disease such as obesity, fatty liver.Although currently there are many lipid lowerers, fat-reducing medicament
Need long-term taking and all there are many side effect, such as lipid-lowering statins, occasionally there are hepatic injury, myasthenia, rare striped muscle
Dissolving and immune disease etc..
The task of top priority is a kind of long-term taking of research and development and the Medicines and Health Product being free from side effects, used as probiotic bacteria and probiotics
Butyric acid bacteria and inulin gradually enter into the visual field of people.
Butyric acid bacteria, also known as Clostridium butyricum, its major function and characteristic are：（1）Promote the increment of intestinal beneficial flora and send out
Educate, suppress the growth and breeding of harmful bacteria and putrefaction bacteria in intestinal, intestinal flora disorder is corrected, reduces the generation of enterotoxin,
Significant to adjusting intestinal microecology；（2）Butyric acid bacteria energy activating immune system, promotes immunologic function, maintains body
Health status, there are some researches show that butyric acid bacteria cell has antitumor vigor；（3）In the intestinal butyric acid bacteria can produce vitamin B group,
The materials such as vitamin K, amylase, with health role to body；（4）The main metabolites of butyric acid bacteria are butyric acid, and butyric acid
It is intestinal epithelial cell regeneration and the Major Nutrient material that repairs.Therefore, the regeneration that gut epithelium is organized and reparation have very heavy
The meaning that wants；（5）Butyric acid bacteria is anaerobic spore-bearing bacilli, endogenous spore, good stability, does not receive gastric acid, bile acid etc. in human body
Impact, can preserve under room temperature more than 3 years in vitro, and have stronger toleration to Multiple Classes of Antibiotics.
Inulin is deposit property polysaccharide in plant, is mainly derived from plant.China's major part is with Jerusalem artichoke at present（Jerusalem artichoke）Root shape
Stem is raw material, removes removing protein, colloid, crude fibre and mineral etc., obtains inulin.Inulin is most of to be reached greatly with complete form
Intestinal, is alternatively be nutrient substance by the beneficial microbe such as bacillus bifiduss, lactic acid bacteria in intestinal, and the harmful bacteria such as escherichia coli
Low to the utilization rate of inulin.Inulin plays intestinal physiology effect to be had：（1）Contain on the cell surface of many pathogenic microorganisms or pili
Have lectin, can be combined with the specific receptors in gut epithelium, can indirect action or produce toxin, cause animal fall ill.
After adding inulin, inulin can be specifically bound with the lectin of pathogen, it is to avoid pathogen is adhered on intestinal, with chrysanthemum
Powder is excreted from digestive tract, so as to the pathogen that eluting has been adhered to；（2）After inulin is fermented in colon, microbial bacteria is improved
Group and gas flow, increased osmotic pressure, so as to promote intestinal peristalsis promoting, reduce the reabsorption of moisture and electrolyte；（3）Inulin pair
Intestinal tissue has protective effect, can improve mucosa cells density, labelling cell number etc..
104415061 A of Chinese patent CN discloses one kind the invention provides edible composition and preparation method thereof
And purposes.The edible composition of the invention includes：Weight ratio is 1.2-2：1 inulin and clostridium butyricum.In
A kind of functional oligose and probiotic composition are disclosed in 10441334 A of state's patent CN.These combinations can be notable
The quantity of animal intestinal probiotic bacteria is improved, suppresses the growth of harmful bacteria and harmful substance, so as to effectively adjust microbial population of animal intestinal tract,
And then effect enhancing immunity based on intestinal microbial population, prevention or treatment obesity, diabetes, hypertension, hyperlipidemia or tumor etc.
Disease.
We have found, the inulin content that mentions in patent is low through research, are not golden ratio, it is impossible to make butyric acid bacteria and
Inulin coordinative role reaches maximization.In intestinal, probioticss also have bacillus bifiduss, lactobacilluss etc. except butyric acid bacteria, inulin with
Sample can promote its growth, and inulin ratio is high, can preferably play intestinal physiology effect, set up intestinal microecology.
Content of the invention
It is an object of the invention to provide a kind of butyric acid bacteria-inulin composition with functions, this compositionss have optimal proportion, can
The performance for making the synergistic function of inulin and butyric acid bacteria obtain incisively and vividly, effectively adjusts microbial population of animal intestinal tract, makes butyric acid bacteria
Decompose inulin and a large amount of biological active substanceies-butyric acid are produced, peroxide activator enzyme system is united, prevent or treat fat, hyperlipidemia
Deng.
It should be noted that the term " animal " in the expression way " regulation microbial population of animal intestinal tract " for herein being used
The animal species of indication are not particularly limited.Embodiments in accordance with the present invention, the animal can be any with intestinal organ
Animal, preferably mammal, more preferably rat, mice, people, optimum is chosen.
The present invention solves its technical problem and is adopted the technical scheme that：
A kind of butyric acid bacteria-inulin composition with functions, is 3 ~ 8 including mass ratio:1 inulin and butyric acid bacteria.
Used as optimized, the mass ratio of the inulin and the butyric acid bacteria is 5 ~ 8:1.
Used as optimized, the mass ratio of the inulin and the butyric acid bacteria is 6 ~ 7:1.
Used as optimized, the grain diameter of the inulin and the butyric acid bacteria is no more than 800 microns.
Used as optimized, the viable count of the butyric acid bacteria is not less than 1.0*108CFU/g.
Used as optimized, the compositionss also include additive and excipient.
As optimized, the compositionss are in powder, capsule, pill, tablet, granule, in liquid oral at least
A kind of form.
Used as optimized, it is the daily 300mg ~ 600mg butyric acid bacteria of adult that the compositionss eat dosage.
A kind of method for preparing butyric acid bacteria-inulin composition with functions, the inulin of predetermined weight ratio and butyric acid bacteria are uniformly mixed.
Used as optimized, the compositionss purposes makes butyric acid bacteria decompose inulin generation a large amount of for adjusting microbial population of animal intestinal tract
Biological active substanceies-butyric acid, peroxide activator enzyme system unite, prevention or treatment obesity, diabetes, hypertension, hyperlipidemia or
Tumor.
The invention has the beneficial effects as follows：All raw materials are pure natural raw material, safe and reliable, without any side effects, and
Without any chemicals；Prescription compatibility is scientific and reasonable, determined curative effect, with synergistic function, preparation process is simple, easily grasps
Make.Microbial population of animal intestinal tract, enhancing immunity can significantly be adjusted.
Description of the drawings
Fig. 1 C57BL6 mouse liver peroxisome quantity figure；
In figure：Left figure：Vehicle：Matched group, the mice of excipient of ingesting；CBM+inulin：Experimental group, ingest butyric acid bacteria-bacterium
The mice of powder；White fluorescent point represents peroxisome.Right figure：Peroxisomes：Peroxisome number.
Fig. 2 C57BL6 average mice body weight growth chart；
In figure：Percentage increase in body weight：Percentage body weight increase；Days on CBM-Inulin
treatment：Feeding natural law；CBM-inulin：Experimental group, the mice of high lipid food-butyric acid bacteria-mycopowder of ingesting；Vehicle：
Matched group, the mice of high lipid food-excipient of ingesting.
Fig. 3 C57BL6 mice serum triglyceride concentration figure；
In figure：serum triglyceride：Serum triglycerides；CBM-inulin：Experimental group, high lipid food-butyric acid of ingesting
The mice of bacterium-mycopowder；Vehicle：Matched group, the mice of high lipid food-excipient of ingesting.
Fig. 4 C57BL6 mouse liver neutral fat accumulation graph.
In figure：Control represents the mice of high lipid food of not ingesting, and HFD represents the little of high lipid food-excipient of only ingesting
Mus, HFD-CBM-Inulin represents the mice of high lipid food-butyric acid bacteria-inulin composition with functions of ingesting,
Specific embodiment
Embodiments of the invention are described below in detail, embodiment is exemplary, are only used for the present invention is explained, and can not manage
Solve as limitation of the present invention.Unreceipted particular technique or condition in embodiment, according to described by document in the art
Technology or condition or carry out according to product description.
Embodiment 1：
3 weight portion of inulin, 1 weight portion of butyric acid bacteria is weighed, is crushed using disintegrating apparatus processing, obtain granular preparation and be 300 microns
Inulin, the fine powder of butyric acid bacteria, which is uniformly mixed, makes powder.
Embodiment 2：
4 weight portion of inulin, 1 weight portion of butyric acid bacteria is weighed, is crushed using disintegrating apparatus processing, obtain granular preparation and be 400 microns
Inulin, the fine powder of butyric acid bacteria, which is uniformly mixed, makes powder.
Embodiment 3：
5 weight portion of inulin, 1 weight portion of butyric acid bacteria is weighed, is crushed using disintegrating apparatus processing, obtain granular preparation and be 500 microns
Inulin, the fine powder of butyric acid bacteria, which is uniformly mixed, makes powder.
Embodiment 4：
6 weight portion of inulin, 1 weight portion of butyric acid bacteria is weighed, is crushed using disintegrating apparatus processing, obtain granular preparation and be 100 microns
Inulin, the fine powder of butyric acid bacteria, which is uniformly mixed, then content material is placed in soft capsule pellet press, according to existing soft
The filling of capsule manufacture technology is pressed into soft capsule.
Embodiment 5：
7 weight portion of inulin, 1 weight portion of butyric acid bacteria is weighed, is crushed using disintegrating apparatus processing, obtain granular preparation and be 300 microns
Inulin, the fine powder of butyric acid bacteria, which is uniformly mixed, according to existing granule production technology, makes granule.
Embodiment 6：
8 weight portion of inulin, 1 weight portion of butyric acid bacteria is weighed, is crushed using disintegrating apparatus processing, obtain granular preparation and be 200 microns
Inulin, the fine powder of butyric acid bacteria, which is uniformly mixed, then tabletting is carried out according to existing tablet manufacturing technology, do piece agent.
Embodiment 7：As shown in figure 1, experimental group CBM+Inulin gives C57BL6 mice butyric acid bacteria-inulin composition with functions 2 weeks,
Vehicle represents matched group, that is, the mice of excipient of ingesting, and detects the peroxisome proliferation situation of liver.Left side in Fig. 1
Figure is to observe hepatic peroxisomes using laser confocal microscope, and wherein white fluorescent point represents peroxisome.
It can be seen that experimental group C57BL6 mice ingests compared with matched group, the peroxide of internal liver after butyric acid bacteria-inulin composition with functions
Compound enzyme body number is dramatically increased, and demonstrating butyric acid bacteria-inulin can stimulate liver to produce more peroxisomes.Right part of flg
Piece vertical coordinate represents the quantity of peroxisome, intuitively finds out from figure, after butyric acid bacteria-inulin composition with functions of ingesting, mice
Peroxisome number in liver increases.
Embodiment 8：High fat diet fat animal model is made, CBM-Inulin represents experimental group, gives 20 C57BL6
40% high lipid food of mice（HFD）, while giving placebo and 8% butyric acid bacteria-inulin composition with functions, Vehicle represents matched group, right
20 40% high lipid foods of C57BL6 mice are given according to group（HFD）, while placebo and 8% excipient is given, using prunus mume (sieb.) sieb.et zucc. Teller-support
Benefit electronic scale records average mice body weight growth pattern, continuous record 2 weeks, as shown in Figure 2.In figure can be seen that cheese of ingesting
The Mouse Weight growth rate of sour bacterium-inulin does not ingest butyric acid bacteria-inulin mice slowly, i.e.,：Butyric acid bacteria-mycopowder can slow down little
The growth rate of Mus body fat.
As shown in figure 3, after 8 weeks using full-automatic biochemical instrument detection matched group and experimental mice blood in triglyceride with
The neutral fat of evaluating liver piles up situation, finds the HFD that equally ingests, and experimental group is ingested the mice of butyric acid bacteria-inulin composition with functions
In blood, the concentration of triglyceride is significantly reduced compared with matched group.
As shown in figure 4, bleachinging and dyeing liver using oil red o staining, oil red o is very strong fatsolvent and dye fat agent, and energy is specifically
Tissue and three ester of intracellular neutral glycerine, lipid and lipoprotein etc. is made to property to dye redness,（Due to Fig. 4 white and black displays, middle
In picture and Image to right, black deeper portion is three ester of neutral glycerine and oil red o specific bond）By microscope collection figure
As the athero situation in evaluating liver.It is found that butyric acid bacteria-inulin composition with functions can effectively suppress the heap of liver neutral fat
Product, its microscope collection picture is little with the mice picture difference of high lipid food of not ingesting, and further relates to suppress sending out for fatty liver
Give birth to, play a part of to prevent and treat hyperlipidemia, fatty liver diseases.
A kind of butyric acid bacteria-inulin composition with functions of the present invention and its production and use, by the flat of regulating intestinal canal flora
Weigh, butyric acid bacteria can decompose using the substantial amounts of active physiological substances-butyric acid of inulin generation in this process, and butyric acid induces Pex11a base
Cause and peroxisome system, therefore without any toxic and side effects, and then the effect enhancing immunity based on intestinal microbial population, in advance
The disease such as anti-or treatment obesity, diabetes, hypertension, hyperlipidemia or tumor.
Above-mentioned specific embodiment is only the concrete case of the present invention, and the scope of patent protection of the present invention is included but is not limited to
The product form of above-mentioned specific embodiment and style, a kind of any butyric acid bacteria-inulin group for meeting claims of the present invention
Appropriate change or repair that compound and its production and use and any person of an ordinary skill in the technical field are done to which
Decorations, should all fall into the scope of patent protection of the present invention.
Claims (10)
1. a kind of butyric acid bacteria-inulin composition with functions, it is characterised in that：It is 3 ~ 8 including mass ratio:1 inulin and butyric acid bacteria.
2. a kind of butyric acid bacteria-inulin composition with functions according to claim 1, it is characterised in that：The inulin and the butyric acid
The mass ratio of bacterium is 5 ~ 8:1.
3. a kind of butyric acid bacteria-inulin composition with functions according to claim 1, it is characterised in that：The inulin and the butyric acid
The mass ratio of bacterium is 6 ~ 7:1.
4. a kind of butyric acid bacteria-inulin composition with functions according to claim 1, it is characterised in that：The inulin and the butyric acid
The grain diameter of bacterium is no more than 800 microns.
5. a kind of butyric acid bacteria-inulin composition with functions according to claim 1, it is characterised in that：The viable count of the butyric acid bacteria
It is not less than 1.0*108CFU/g.
6. a kind of butyric acid bacteria-inulin composition with functions according to claim 1, it is characterised in that：The compositionss also include to add
Plus agent and excipient.
7. a kind of butyric acid bacteria-inulin composition with functions according to claim 1, it is characterised in that：The compositionss are in powder, glue
At least one form in wafer, pill, tablet, granule, liquid oral.
8. a kind of butyric acid bacteria-inulin composition with functions according to claim 1, it is characterised in that：The compositionss eat dosage
For the daily 300mg ~ 600mg butyric acid bacteria of adult.
9. the method that one kind prepares any one butyric acid bacteria-inulin composition with functions in claim 1 ~ 8, it is characterised in that：By predetermined weight
The inulin of amount ratio and butyric acid bacteria uniformly mix.
10. according to any one butyric acid bacteria-inulin composition with functions in claim 1 ~ 8, it is characterised in that：The compositionss purposes is for adjusting
Section microbial population of animal intestinal tract, makes butyric acid bacteria decompose inulin and produces a large amount of biological active substanceies-butyric acid, peroxide activator enzyme system
System, prevention or treatment obesity, diabetes, hypertension, hyperlipidemia or tumor.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610937943.6A CN106420839A (en) | 2016-10-25 | 2016-10-25 | Clostridium butyricum-inulin composition as well as preparation method and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610937943.6A CN106420839A (en) | 2016-10-25 | 2016-10-25 | Clostridium butyricum-inulin composition as well as preparation method and application thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN106420839A true CN106420839A (en) | 2017-02-22 |
Family
ID=58178930
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610937943.6A Pending CN106420839A (en) | 2016-10-25 | 2016-10-25 | Clostridium butyricum-inulin composition as well as preparation method and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN106420839A (en) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101624611A (en) * | 2009-08-13 | 2010-01-13 | 浙江大学 | Preparation method of inulase zymolyte for promoting clostridium butyricum to grow |
| CN104415061A (en) * | 2013-08-30 | 2015-03-18 | 深圳华大基因科技有限公司 | Edible composition as well as preparation method and application thereof |
| CN104740138A (en) * | 2013-12-31 | 2015-07-01 | 深圳华大基因科技有限公司 | Composition containing aloe, probiotics and prebiotics and application of composition |
-
2016
- 2016-10-25 CN CN201610937943.6A patent/CN106420839A/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101624611A (en) * | 2009-08-13 | 2010-01-13 | 浙江大学 | Preparation method of inulase zymolyte for promoting clostridium butyricum to grow |
| CN104415061A (en) * | 2013-08-30 | 2015-03-18 | 深圳华大基因科技有限公司 | Edible composition as well as preparation method and application thereof |
| CN104740138A (en) * | 2013-12-31 | 2015-07-01 | 深圳华大基因科技有限公司 | Composition containing aloe, probiotics and prebiotics and application of composition |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Ranjha et al. | Nutritional and health potential of probiotics: a review | |
| CN103484288B (en) | Method for improving effect of medicinal liquor and probiotic composition | |
| CN101366734A (en) | Synbiotics medicament composition | |
| CN112716982B (en) | Lactic acid bacteria-containing composition and use thereof | |
| CN104415061B (en) | Edible composition and its production and use | |
| CN109481510A (en) | It is a kind of to help to improve diabetes B and its synbiotic compound preparation of complication and preparation method thereof | |
| CN108029885A (en) | Pet care product and preparation method thereof | |
| JP5592640B2 (en) | Antistress agent containing lactic acid bacteria fermented royal jelly, method for producing the same, hypothalamus-pituitary-adrenocortical activity inhibitor, and sympathetic-adrenal medullary activity inhibitor | |
| CN103446552B (en) | For the fermentation composition of prevention and therapy digestive system disease | |
| JP2013014617A (en) | Method of improving immune function in mammal using 3-hpa producing lactobacillus strain in combination with medium chain triglyceride oil | |
| KR102095967B1 (en) | Method for Incubating Functional Microalgae for Immune Management and Nutrition Management of Livestock and their products, Fermented Medicinal Herb Ionized Mineral Composition Using it, and Method for manufacturing thereof | |
| US10500236B2 (en) | Bioactive animal feed | |
| CN110710660A (en) | Blood sugar lowering composition and dietary supplement containing bitter gourd powder | |
| CN103875977A (en) | Mixed feed for aquaculture | |
| CN108782963A (en) | It is a kind of can antibacterial improve immunity probiotics and preparation method thereof | |
| CN1258994C (en) | Fruit vinegar chewing tablet food and its preparation method | |
| CN110074392A (en) | A kind of Antialcoholic liver-protecting nourishing the stomach shield intestines composition and preparation method thereof | |
| CN109965290B (en) | Meal replacement powder for improving intestinal flora and application thereof | |
| Derkanosova et al. | Blood chemistry values and histological features of the gastrointestinal tract in young rabbits when using probiotic agents in feeding diets | |
| CN106420839A (en) | Clostridium butyricum-inulin composition as well as preparation method and application thereof | |
| CN112021575A (en) | Probiotic composition and preparation method thereof | |
| CN1058377C (en) | Fowl and animal fodder additive with seed bacteria prepared by mixing various living bacteria for processing food | |
| WO2023000408A1 (en) | COMPOSITION COMPRISING β-NICOTINAMIDE MONONUCLEOTIDE AND ROXBURGH ROSE EXTRACT, AND APPLICATION THEREOF | |
| CN106692452A (en) | Preparation method for traditional Chinese medicine component | |
| TWI458438B (en) | Fermentation and culture methods, plant fermentation extracts, plant fermentation extract powders, and plant fermentation extract complexes |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20170222 |